News from myr pharma A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Mar 05, 2019, 11:13 ET MYR Pharma Announces Grant of Promising Innovative Medicine (PIM) Designation by British MHRA for Bulevirtide (Myrcludex), the First-in-Class Entry Inhibitor for Treatment of Chronic Hepatitis D Infections

MYR Pharma announced today that the British Medicines and Healthcare products Regulatory Agency (MHRA) has issued the Promising Innovative Medicine...


Oct 29, 2018, 04:50 ET MYR Pharma Announces Presentation of Interim Results of MYR 203, a Phase 2 Study of Myrcludex in Combination with Pegylated Interferon in Chronic Hepatitis Delta

MYR Pharma today announced that the results of 48 weeks of administration of Myrcludex, MYR`s first-in-class entry inhibitor for treatment of...


Oct 23, 2018, 11:46 ET MYR Pharma Announces Grant of Breakthrough Therapy Designation by US FDA for Myrcludex, the First-in-Class Entry Inhibitor for Treatment of chronic Hepatitis B and D Infections

MYR Pharma today announced that US Food and Drug Administration (FDA) has granted the Breakthrough Therapy designation for its lead compound...


Mar 27, 2018, 10:21 ET MYR Pharma Announces Multiple Presentations at the European Association for the Study of the Liver (EASL) Meeting

MYR Pharma GmbH, focused on the development of Myrcludex B, a novel drug for the treatment of Hepatitis B and Delta, today announced a number of oral ...


Mar 12, 2018, 11:04 ET MYR Pharma Completes Clinical Trial of Myrcludex B in Chronic Hepatitis Delta

MYR Pharma GmbH today announced the completion of its MYR 202 clinical trial, a Phase 2b study investigating Myrcludex B in chronic hepatitis Delta...


Feb 22, 2018, 11:13 ET MYR Pharma Announces Completion of Active Treatment Phase in MYR 203 Clinical Trial of Myrcludex B

MYR Pharma GmbH today announced the completion of the 48-week-long active treatment phase in MYR 203 clinical trial, a part of Phase 2b program...